Sana Biotechnology Announces Positive Clinical Results From Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana生物技術宣佈無免疫抑制的1型糖尿病胰島電芯移植研究獲得積極臨牀結果
Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses.
Sana生物技術發佈了它評估的糖尿病1型治療研究的積極數據。該公司表示，它在不使用任何免疫抑制劑的情況下，將其治療方案UP421（使用其低免疫反應科技工程化的異體原發電芯細胞治療）移植到一名1型糖尿病患者身上。研究沒有發現安全問題，低免疫反應修飾的電芯細胞成功避開了免疫反應。
